

Heart Disease Risks Differ Among Black Women

BY DOUG BRUNK
San Diego Bureau

SAN DIEGO — Biochemical coronary heart disease risk markers differ between young black women born in the United States and those born in other countries, Errol Davis, Ph.D., reported in a poster session at a meeting sponsored by the American Society for Nutritional Sciences.

The finding suggests that physicians "should not assume that all black individuals have the same level of risk in developing coronary heart disease," Dr. Davis, a postdoctoral fellow in the department of dietetics and nutrition at Florida International University, Miami, told this newspaper. "Health care professionals designing or managing programs to reduce coronary heart disease in ethnic populations should respond to the specific needs of the different groups within this same race for more effective outcomes."

In a cross-sectional study conducted with his associate Fatma Huffman, Ph.D., Dr. Davis analyzed the blood lipids and levels of high-sensitivity C-reactive protein (hs-CRP) in 35 foreign-born Afro Caribbean American women living in the United States for fewer than 10 years, 32 Afro Caribbean women born in the United States, and 31 African American women. The women ranged in age from 18 to 40 years.

The investigators observed no significant differences among the three groups in terms of mean total cholesterol, LDL cholesterol, and HDL cholesterol. However, the mean hs-CRP levels were significantly lower in foreign-born Afro Caribbean American women and Afro Caribbean women born in the United States, compared with levels in African American women (1 mg/L, 1.1 mg/L, and 2.4 mg/L, respectively).

In addition, elevated hs-CRP levels de-

finied as greater than 3 mg/L were observed in 10% of foreign-born Afro Caribbean American women, 7.4% of Afro Caribbean women born in the United States, and 30% of African American women.

"We were not totally surprised by the results," Dr. Davis said. "South Florida is a cultural melting pot due to its ethnically diverse population. We previously observed differences in behavioral habits between foreign-born and U.S.-born individuals of African ancestry. There are data indicating

that the death rate due to coronary heart disease in foreign-born individuals was lower than that of their U.S.-born counterparts. It was our theory that biochemical differences with respect to coronary heart disease would also exist. However, there was no evidence in the literature for this assumption. Hence, the importance of our research." He added that because the study was small and its participants were from a university setting, the findings may not be generalizable to all black women. ■

Classic Symptoms May Miss CHD in Younger Women

NEW YORK — Premenopausal women who undergo cardiac catheterization for classic symptoms of coronary heart disease may be less likely to have findings of the disease than women without those symptoms, according to a small retrospective study.

Andra L. Blomkalns, M.D., of the University of Cincinnati and her colleagues identified 169 premenopausal women (younger than 50 years) who underwent cardiac catheterization (defined as having a stent or angioplasty), from a multicenter registry of 17,713 patients who had a complaint of chest pain and received electrocardiography. Of the 169 patients, 53 (31%) had significant coronary artery disease or stenosis greater than 70%.

A set of factors that put premenopausal women at a significantly increased risk for coronary heart disease (CHD) included increasing age, a moderate- or high-risk initial impression, a history of CHD, and positive cardiac markers. In a multivariate model, this set of risk factors predicted CHD with an accuracy of about 80%, Dr. Blomkalns reported in a poster session at the annual meeting of the Society for Academic Emergency Medicine.

The classic symptoms of CHD such as shortness of breath and pain radiating to the chest or left arm were not significantly associated with an increased risk for CHD in the premenopausal women.

—Jeff Evans

And Now for the Good News

Pain relievers... Study cites... called... risk

COX-2 drugs have... from sale... On S... manufac... cardiovasc... The decision... Adenomatous Pol... trial for the preventi... The world's biggest... the risk of heart...

More concerns... the company says... the same class may... or strokes. A research... has told two panels of advisers that... since the company pulled the cox-2... the market last year, studies sugges... similar problems with other drugs...

EASY OPEN CAP

ALL DAY STRONG

ALEVE

naproxen sodium tablets 220 mg Pain reliever / fever reducer

EASY OPEN ARTHRITIS CAP

CAPLETS*

*CAPSULE - SHAPED TABLET(S)

Ease-of-Use Commendation For Packaging ARTHRITIS FOUNDATION www.arthritis.org

With ALEVE®, you can still provide a strong and safe pain reliever for your patients with OA

Proven strength that lasts

- ALEVE is the **ONLY OTC** brand pain reliever containing naproxen — with 12-hour dosing strength
- Vs ibuprofen, ALEVE provided significantly greater relief of nighttime OA pain[†]
- Vs acetaminophen, ALEVE provided significantly greater relief of patient-reported morning stiffness^{††}

Established safety profile^{2,3}

- More than 28 years of clinical experience as naproxen
- More than 550 million courses of therapy[†]

Share the good news with your patients. Recommend ALEVE.
SAFE AND STRONG. ALL DAY LONG.

* In a randomized, double-blind, placebo-controlled, 7-day study of 301 patients. Other measures of relief were comparable. † In a randomized, double-blind, placebo-controlled, 7-day study of 303 patients. Based on patient assessments on Day 2. Other measures of relief were comparable. †† Course of therapy defined as 2 tablets/day for 10 consecutive days.

References: 1. Data on file. Bayer HealthCare LLC. 2. Bansal V, Dex T, Proskin H, Garreffa S. A look at the safety profile of over-the-counter naproxen sodium: a meta-analysis. *J Clin Pharmacol*. 2001;41:127-138. 3. DeArmond B, Francisco CA, Lin J-S, et al. Safety profile of over-the-counter naproxen sodium. *Clin Ther*. 1995;17:587-601.

© 2005 Bayer HealthCare LLC

June 2005

25454